Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world
  • Posted by Claire Fradet Aubignat
  • June 29, 2020
  • Articles

Not just another PSP: 5 top tips for evaluating your patient support programme

Not just another PSP: 5 top tips for evaluating your patient support programme

Evaluating PSPs before launch is critical. We present you with our top tips for conducting successful market research to ensure your PSP is successful and maximises value to your customers.

Did you know that, whilst there are a significant number of PSPs available to patients, only a small minority are actually used?  IMS (2015) found that 36 out of almost 200,000 mobile health apps comprised 50% of downloads - many of the rest must have very few users. So, a key challenge is to develop a PSP that is utilised, valued and has a definite real world impact on both the patient and HCP experience.

read more »

  • Posted by Brett Gardiner, Rachel Howard & Suzan Serip
  • June 12, 2020
  • Articles

The unprecedented challenge of pricing a coronavirus vaccine

The unprecedented challenge of pricing a coronavirus vaccine

Using findings from our recent COVID-19 impact study, Market Access Directors Rachel Howard and Brett Gardiner and Consultant Suzan Serip explore the challenges of pricing a coronavirus vaccine. Read our latest article for pharmaphorum.

The optimal pricing strategy for a new vaccine involves setting a fair and sustainable price that enables the eligible population in need across the world to gain access, while also rewarding innovation and supporting further research and development. The need for a SARS-CoV-2 vaccine is arguably more urgent, and more global, than ever before for a vaccine. As the 130+ vaccine candidates currently in development progress through clinical testing, a key question for their manufacturers is how COVID-19 might be changing the equation when it comes to what a responsible pricing strategy might look like. At the same time, payers are also faced with needing to prepare and plan for how to react and manage this situation.

read more »

  • Posted by Rachel Howard, Brett Gardiner & Richa Munjal
  • June 8, 2020
  • Articles

Breaking policy and perceptual barriers: Biosimilars

Breaking policy and perceptual barriers: Biosimilars

Our specialist market access and Therapy Watch teams analyse RA prescribing data to identify how market access policies across Europe may have impacted the adoption of biosimilars. Read our latest article for pharmaphorum's Deep Dive.

Biologics are big business in Rheumatoid Arthritis (RA), with the first wave of TNF inhibitors Remicade (infliximab), Enbrel (etanercept) and Humira (adalimumab) all having achieved blockbuster sales since their launches in the early 2000s. In recent years, as patents started to expire, an increasing number of branded and generic pharmaceutical companies have launched biosimilars, offering meaningful discounts relative to the originators – an appealing proposition for strained healthcare systems under pressure to contain costs. Leveraging over two years of syndicated RA Therapy Watch data* from September 2017-December 2019 in France, Germany, UK, Italy, and Spain, we looked into what parallels could be drawn between country trends in biosimilar prescribing and individual market policies designed to promote their use.

read more »

  • Posted by John Branston
  • April 29, 2020
  • Articles

Is medical conference marketing now a long-distance relationship?

Is medical conference marketing now a long-distance relationship?

As more medical conferences plan to go virtual, John Branston reflects on the results of a study conducted among several hundred medical specialists about the future of these events and outlines how conference research is still possible in the age of COVID-19

As we all re-organise multiple aspects of our lives around new imperatives forced on us locally and globally by the coronavirus pandemic, it is worthwhile to think about how the short-term solutions we devise to achieve our objectives in the face of current limitations may have a long-lasting effects on familiar activities and behaviours.

read more »

  • Posted by Angela Duffy
  • March 18, 2020
  • Articles

Mapping the patient journey and minding the gap: Seven steps to closing the gap between rhetoric and reality in patient-centricity

Mapping the patient journey and minding the gap: Seven steps to closing the gap between rhetoric and reality in patient-centricity

Senior Director Angela Duffy was recently interviewed by PME Magazine about the steps needed to close the gap between rhetoric and reality in patient-centricity, and why it’s vital to include patients in every step.

“When I grew up in the industry, things were pretty well set in terms of how pharmaceutical companies engaged with patients - which is to say that you didn’t engage all that much.” Ron Cohen’s reflection on ‘Pharma Past’ will be familiar to many who worked in the industry in the era before patient-centricity became the biggest of buzzwords. Speaking to McKinsey in 2016, the biotech CEO argued that a new generation of engagement was dawning. 

read more »